Arbutus Biopharma (ABUS) Free Cash Flow (2013 - 2026)
Arbutus Biopharma (ABUS) posted Free Cash Flow of -$8.1 million for Q1 2026, down 73.29% sequentially from -$4.7 million in Q4 2025, and up 39.44% YoY from -$5.8 million in Q1 2025.
Arbutus Biopharma (ABUS) Free Cash Flow (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported Free Cash Flow for 14 years, with the latest figure at -$8.1 million in Q1 2026.
- Quarterly Free Cash Flow rose 39.44% year-over-year to -$8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.4 million (up 41.8% YoY) and the FY2025 annual result came in at -$39.6 million, up 39.05% from the prior year.
- Free Cash Flow eased to -$8.1 million in Q1 2026 per ABUS's latest filing, from -$4.7 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $20.5 million in Q1 2022 and troughed at -$27.4 million in Q1 2023.
- A 5-year average of -$13.9 million and a median of -$17.1 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 214.26% in 2022, then tumbled 233.46% in 2023.
- Over 5 years, Free Cash Flow stood at -$17.1 million in 2022, then dropped by 0.98% to -$17.3 million in 2023, then soared by 39.85% to -$10.4 million in 2024, then surged by 55.0% to -$4.7 million in 2025, then slumped by 73.29% to -$8.1 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$8.1 million, -$4.7 million, and -$5.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - | -6.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.02 Mn |
| Jun 30, 2026 | -6.02 Mn |
| Mar 31, 2026 | -8.11 Mn |
| Mar 31, 2026 | -8.11 Mn |
| Dec 31, 2025 | -4.68 Mn |
| Dec 31, 2025 | -4.68 Mn |
| Sep 30, 2025 | -5.82 Mn |
| Sep 30, 2025 | -5.82 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Jun 30, 2025 | -15.75 Mn |
| Mar 31, 2025 | -13.39 Mn |
| Mar 31, 2025 | -13.39 Mn |
| Dec 31, 2024 | -10.40 Mn |
| Dec 31, 2024 | -10.40 Mn |
| Sep 30, 2024 | -20.74 Mn |
| Sep 30, 2024 | -20.74 Mn |
| Jun 30, 2024 | -14.51 Mn |
| Jun 30, 2024 | -14.51 Mn |
| Mar 31, 2024 | -19.39 Mn |
| Mar 31, 2024 | -19.39 Mn |